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Abstract 20 
Most bacteria in nature exist in aggregated communities known as biofilms. Bacteria 21 
within biofilms are inherently highly resistant to antibiotics. Current understanding of 22 
the evolution and mechanisms of antibiotic resistance is largely derived from work 23 
from cells in liquid culture and it is unclear whether biofilms adapt and evolve in 24 
response to sub-inhibitory concentrations of drugs. Here we used a biofilm evolution 25 
model to show that biofilms of a model food borne pathogen, Salmonella 26 
Typhimurium rapidly evolve in response to exposure to three clinically important 27 
antibiotics. Whilst the model strongly selected for improved biofilm formation in the 28 
absence of any drug, once antibiotics were introduced the need to adapt to the drug 29 
was more important than the selection for improved biofilm formation. Adaptation to 30 
antibiotic stress imposed a marked cost in biofilm formation, particularly evident for 31 
populations exposed to cefotaxime and azithromycin. We identified distinct 32 
resistance phenotypes in biofilms compared to corresponding planktonic control 33 
cultures and characterised new mechanisms of resistance to cefotaxime and 34 
azithromycin. Novel substitutions within the multidrug efflux transporter, AcrB were 35 
identified and validated as impacting drug export as well as changes in regulators of 36 
this efflux system. There were clear fitness costs identified and associated with 37 
different evolutionary trajectories. Our results demonstrate that biofilms adapt rapidly 38 
to low concentrations of antibiotics and the mechanisms of adaptation are novel. 39 
This work will be a starting point for studies to further examine biofilm specific 40 
pathways of adaptation which inform future antibiotic use. 41 
  42 
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Main 43 
Antimicrobial resistance (AMR) is a complex problem and is a major threat to human 44 
and animal health (1). Understanding how bacteria develop resistance to antibiotics 45 
is important to inform how they should be used to minimise selection of AMR. There 46 
are many genetic mechanisms of antibiotic resistance and the selection of resistant 47 
mutants is a classic example of natural selection (2). Initial studies of mechanisms of 48 
resistance tended to expose populations to very high concentrations of antibiotics 49 
and select for survivors. This identified ‘high-impact’ mutations can confer a large 50 
phenotypic benefit and proved very useful for characterising cellular targets and 51 
primary resistance mechanisms. However, more recent work has found that 52 
repeated exposure to sub-inhibitory concentrations of antimicrobials can have 53 
profound impacts on bacterial populations including selection for high level 54 
resistance (3,4). This better reflects real world situations where low levels of 55 
antimicrobials are commonly present. Importantly, this allows epistatic interactions 56 
between multiple genes to be selected and for fitness costs arising from resistance 57 
mutations to be ameliorated by additional, compensatory mutations (5). 58 
Much of our understanding of the mechanisms of antibiotic action and resistance 59 
comes from laboratory experiments in which bacteria are routinely grown in liquid 60 
culture before being exposed to antibiotics. Yet most bacteria in nature exist in 61 
biofilms; aggregates of cells often attached to a surface (6).  Biofilms represent a 62 
fundamentally different mode of life to planktonic cultures and multiple studies have 63 
demonstrated extreme changes in gene and protein expression profiles from the 64 
same strains when grown in liquid or as a biofilm (7). Many infections include a 65 
biofilm component which makes the infection difficult to treat; common examples 66 
include infections on prosthetic or indwelling devices. One of the hallmarks of 67 
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biofilms is inherit resistance to antibiotics, when compared to the corresponding 68 
strain grown in liquid culture. One theory explaining the high degree of resistance to 69 
antibiotics in biofilms is that cells within a biofilm are metabolically inactive, or even 70 
‘persisters’. In these dormant subpopulations, characterised by arrested 71 
macromolecular syntheses, the cellular targets which the antibiotics poison are not 72 
essential, thus impeding the bactericidal activity of the antibiotic (8). However, recent 73 
studies have demonstrated a strong evolutionary pressure for strains to evolve 74 
improved biofilms. In particular, rapid selection of mutants and combinations of 75 
mutants with improved biofilm fitness is observed when bacteria are introduced to a 76 
new niche (9–11).  77 
Given this evidence of adaptation within biofilms we were interested whether 78 
exposure to low concentrations of antibiotics would exert a selective effect on cells 79 
within a biofilm. We hypothesised that exposure of biofilms to sub-lethal 80 
concentrations of antibiotics would impart a selective pressure and the outcomes of 81 
this stress would be distinct to those seen in planktonic cells. To test this hypothesis, 82 
we adapted an experimental biofilm evolution model and used Salmonella 83 
Typhimurium as a model biofilm-forming pathogen which we exposed to three 84 
clinically relevant antibiotics. We compared drug exposed biofilm lineages to 85 
unexposed biofilm controls and exposed planktonic lineages. We measured the 86 
emergence of antibiotic resistance, biofilm capacity, and pathogenicity, and 87 
subsequently investigated condition-specific mechanisms of resistance using 88 
genome sequencing. We observed rapid adaptation to antibiotic pressure which 89 
often carried a cost for biofilm formation, identified novel mechanisms of resistance 90 
against cefotaxime and azithromycin and detected biofilm-specific phenotypes 91 
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showing that studying how biofilms adapt to stress is vital to understanding the 92 
evolution of AMR. 93 
Results 94 
A biofilm evolution model can study responses to antimicrobial stress 95 
To study the evolution and adaptation of S. Typhimurium biofilms when exposed to 96 
antibiotics, a serial transfer bead-based model system was adapted and optimised 97 
(based on previous work by the Cooper group (11)). To establish Salmonella 98 
biofilms, we grew bacteria on glass beads in broth (see materials and methods). The 99 
beads served as a substrate for biofilms to form on and as a biofilm transfer vehicle, 100 
used to move mature biofilms to new tubes with fresh media and new sterile beads. 101 
After each transfer, bacteria from the biofilm community had to colonise the new 102 
beads and establish biofilms on their surface before being transferred again. This 103 
system allows repeated longitudinal exposure of biofilms to the stress of interest and 104 
captures all the major components of the biofilm lifecycle.  After each passage, cells 105 
from biofilms were harvested and populations and individual representative strains 106 
were stored and phenotypically characterised. Strains that developed resistance or 107 
exhibited altered biofilm formation were selected for whole-genome-sequencing to 108 
identify the genetic basis of these phenotypes (Figure 1, a-d). 109 
To determine the appropriate conditions for the evolution experiments, we measured 110 
biofilm formation by S. Typhimurium 14028S in lysogeny broth (without salt) after 24, 111 
48, 72 and 96 hours, at 25oC, 30oC, 37oC and 40oC respectively (Figure 1, e). Biofilm 112 
formation was determined by measuring cfu per bead (Figure 1, e). Over 72 hours 113 
the highest amount of biomass formed (~106 cfu/ bead) was after incubation at 25oC 114 
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or 30oC; this was stable and consistent. Therefore, we ran the evolution experiments 115 
at 30oC with a passage period of 72 hours. 116 
To investigate if and how biofilms would adapt to exposure to sub-inhibitory 117 
concentrations of antibiotics, we grew biofilms on beads, in the presence of three 118 
clinically-important antibiotics for the treatment of Salmonellosis; azithromycin, 119 
cefotaxime and ciprofloxacin. The minimum inhibitory concentrations (MICs) for each 120 
antibiotic were determined following the EUCAST microbroth dilution method, 121 
adapted to use LB-NaCl and 30 °C to replicate the experimental conditions. Growth 122 
kinetics in the presence of all three agents were determined at the same conditions. 123 
Based on these results we identified concentrations of each agent (10 μg/mL 124 
azithromycin, 0.062 μg/mL cefotaxime and 0.015 μg/mL of ciprofloxacin) that reliably 125 
restricted planktonic growth rates to approximately 50% of that of unstressed control 126 
cultures which were then used for evolution experiments. This approach had proved 127 
tractable in our previous planktonic evolution experiments with biocides (12).  128 
We ran three separate evolution experiments, one with each antibiotic. Within each 129 
we included eight lineages; four exposed bead lineages, two exposed planktonic 130 
cultures and two drug-free bead-control lineages (Figure 1b). Populations from early, 131 
middle and late time points of each experiment were harvested from beads and three 132 
single colonies were isolated to allow us to examine phenotypic diversity within the 133 
population. The isolates were tested for their biofilm ability, morphology and 134 
susceptibility. Biofilm formation was monitored using the Crystal Violet assay (CV) 135 
assay and matrix production assessed qualitatively by visualising colonies grown on 136 
Congo Red (CR) plates. Susceptibility to antibiotics was measured by determining 137 
MICs using the agar dilution method (13). 138 
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To confirm the model selects for evolution of increased biofilm formation we 139 
phenotyped isolated single cells from drug-free bead-control lineages. We observed 140 
an incremental increase in biofilm formation with unexposed isolated colonies 141 
forming larger and wrinklier biofilms on CR plates and producing more than three 142 
times as much biomass over the course of the experiment (Figure 1, f). This 143 
confirmed the model strongly selects for adaptation to produce biofilms with 144 
increased biomass over time in the absence of any stressor.  145 
Biofilms rapidly evolve and adapt in response to sub-inhibitory antibiotic 146 
concentrations   147 
To test the phenotypic responses of biofilms repeatedly exposed to non-lethal 148 
concentrations of the test antibiotics, we isolated both populations and three 149 
individual strains from each lineage at three different timepoints of all experiments; 150 
early (first passage), mid (half way point) and late (final passage). We characterised 151 
these populations as well as isolated strains for susceptibility to eight clinically-152 
relevant antimicrobials, biofilm formation and colony morphology. We compared 153 
results from the biofilm lineages with the corresponding planktonic lineages run at 154 
the same time (Figure 2).  155 
Biofilms rapidly evolved resistance in response to all three exposures (Figure 2). The 156 
time taken to select for emergence of mutants with decreased susceptibility to the 157 
antibiotics was similar in both biofilm and planktonic lineages. Azithromycin selected 158 
mutants in a stepwise manner with emergence of a population with an 8-fold MIC 159 
increase, followed by selection of highly resistant populations with MICs of 160 
azithromycin 16 times more than the parent strain. The decreased susceptibility of 161 
the azithromycin-exposed lineages became evident at the earliest time point and 162 
was fixed by the mid-point of the experiment (Figure 2 a, b). Cefotaxime 163 
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demonstrated a similar dynamic with both planktonic populations and biofilms 164 
exhibiting decreased susceptibility and maintaining this resistance profile until the 165 
end of the experiment (Figure 2, c-d). Adaptation to ciprofloxacin resistance was 166 
selected by the middle of the experimental period and remained fixed up to the final 167 
timepoint in both biofilm and planktonic lineages (Figure 2 e, f). 168 
While the selection dynamics seemed similar between biofilm and planktonic 169 
lineages at first glance, analysis of the MICs to all the antibiotics tested, revealed 170 
significant differences in the outcomes between biofilm and planktonic conditions. 171 
For instance, whilst planktonic populations, exposed to cefotaxime, become mainly 172 
resistant to cefotaxime, cefotaxime-exposed biofilms exhibited a multidrug resistance 173 
(MDR) phenotype (Figure 2, d). These observations show that whilst the biofilms are 174 
able to develop resistance to the selective antibiotics, the mechanisms are likely to 175 
be distinct to those seen in planktonic culture. 176 
Whilst it is widely accepted that increased biomass and matrix production improves 177 
resilience of biofilms to antimicrobial stress, we observed that biofilm formation itself 178 
is heavily influenced by the selective antibiotic. For example, azithromycin prevented 179 
the strains from adapting and forming better biofilms whereas unexposed biofilms 180 
produced much more biomass over time (Figure 2b). Cefotaxime had a strong 181 
negative effect on biofilm formation, with biofilms exposed to cefotaxime actually 182 
producing less biomass than the starting wild-type strain and being characterised by 183 
pale colony morphology on CR plates (Figure 2d). Ciprofloxacin had less impact on 184 
biofilm formation and biofilms exposed to this drug produced increased biomass over 185 
time, although to only half the level of the control biofilms. As expected, isolates from 186 
planktonic lineages did not form better biofilms over time. On the contrary, 187 
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cefotaxime exposure again selected for weaker biofilms with a pale colony 188 
morphology on CR plates (Figure 2c). 189 
Individual antibiotics select specific pathways to resistance in biofilms 190 
To investigate correlations between development of resistance to different antibiotics 191 
and biofilm formation after each exposure, we compared fold changes in MIC of 192 
antibiotics with fold changes in biofilm formation (Figure 3). Each point on the graphs 193 
represents a single isolated strain from each evolution experiment (blue: 194 
azithromycin exposure, white: cefotaxime exposure, red: cipro exposure, black: drug 195 
free exposed controls). All results were compared to averaged data from the parent 196 
strain (represented as point ‘0,0’ on the graphs). 197 
As expected, strains became resistant to the antibiotic they were exposed to. There 198 
were also examples of selection of cross-resistance to other antibiotics in the 199 
biofilms. For instance, azithromycin-exposed isolates exhibited an MDR phenotype 200 
and demonstrated decreased susceptibility not only to azithromycin, but also to 201 
cefotaxime, chloramphenicol, ciprofloxacin, nalidixic acid, tetracycline and triclosan. 202 
Similarly, the cefotaxime-exposed lineages showed increased MICs of 203 
chloramphenicol and tetracycline. Most of the antimicrobials tested are known 204 
substrates of multidrug efflux pumps (e.g. AcrAB-TolC) except for kanamycin. 205 
Strikingly, this was the only antibiotic to which no cross-resistance was observed. In 206 
fact, cefotaxime exposed isolates became more susceptible to kanamycin than the 207 
parent strains. 208 
Apart from impacts on antibiotic resistance, antibiotic exposure also resulted in major 209 
changes in the strains’ ability to form biofilms. Bacteria exposed to cefotaxime 210 
exhibited severely compromised biofilm ability, whereas azithromycin and 211 
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ciprofloxacin led to inhibition or delayed biofilm adaptation respectively. This analysis 212 
again indicates that exposure to antibiotics prompts selection for resistance even at 213 
sub-inhibitory concentrations, but that this comes at a cost to the ability to form 214 
biofilms. 215 
To identify the mechanisms responsible for the phenotypes described above, we 216 
whole-genome sequenced over 100 strains (selected to represent major phenotypes 217 
of interest and to cover different times in the exposure series for each drug) and 218 
identified changes against the parent strain genome. We sequenced a mixture of 219 
populations and single cells and used data from single-cell strains to analyse the 220 
phylogeny of the mutants (Figure 4a). The results indicated that the different 221 
antibiotics selected for mutants which followed distinct paths of adaptation. There 222 
was little commonality between the drug exposures showing that there is no 223 
universal or generic mechanism of resistance selected for in biofilms. Biofilms 224 
exposed to azithromycin and cefotaxime followed a reproducible and distinct 225 
evolution pattern (Figure 4b, c), whereas in the ciprofloxacin exposure, bacteria 226 
responded to the stress in a number of different ways (Figure 4d). For all drugs, 227 
there was separation of biofilm (darker coloured dots) and planktonic lineages 228 
(lighter coloured dots) apparent in the phylogeny, again demonstrating different 229 
trajectories of selection.   230 
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Azithromycin and cefotaxime select novel mechanisms of resistance based 231 
upon exclusion of drug from target which in turn hinders biofilm formation 232 
We used the whole-genome sequencing data to identify mutations which may 233 
account for potential mechanisms of resistance against the antibiotics of interest. 234 
These include some known mechanisms of resistance (e.g. gyrA mutation renders 235 
bacteria resistant to quinolones (14–16)), as well as Single Nucleotide 236 
Polymorphisms (SNPs) that have never been linked to antimicrobial resistance 237 
before. The sequence data gave us enough information to build solid hypotheses 238 
about the genetic basis for novel mechanisms of resistance against cefotaxime and 239 
azithromycin, which we then tested experimentally using a combination of assays 240 
(Figure 5).  241 
Novel mechanisms of cefotaxime resistance 242 
We first observed that isolates that became resistant to cefotaxime had two unique 243 
substitutions that they acquired at different timepoints during the evolution 244 
experiment. The first substitution was in EnvZ (corresponding to arginine 397 to 245 
histidine) and the second was in AcrB (glutamine 176 to lysine). 246 
EnvZ is an osmolarity-sensor protein, attached to the inner membrane of the cell. It 247 
functions both as a histidine kinase and a phosphatase, exerting its activity by 248 
altering the phosphorylation levels of its cognate transcriptional regulator OmpR. 249 
OmpR, amongst other functions, is responsible for differential regulation of the 250 
expression of OmpC and OmpF, two principal outer-membrane porins (17,18), as 251 
well as curli biosynthesis through the csgD-csgBAC operon (19). Mutants carrying 252 
the substitution of R397H in EnvZ exhibited a 4-fold increase in the MIC of 253 
cefotaxime (Figure 5a) of cefotaxime and produced pale colonies on CR plates. This 254 
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substitution was present in both planktonic cultures and in biofilms. It is well 255 
established that β-lactams cross the outer membrane via porin channels and 256 
particularly through OmpF (20–22). It is also well known that OmpR stimulates curli 257 
biogenesis by promoting expression of CsgD, which in turn activates the curli operon 258 
(23).  259 
AcrB is a key component of the tripartite multidrug efflux pump AcrAB-TolC, and is 260 
responsible for substrate recognition and energy transduction (24–26) during the 261 
efflux process. Being a member of the Resistance Nodulation cell Division (RND) 262 
family, AcrB shares a common structural organisation with other RND pumps, and 263 
couples inward proton transport to antiport (efflux) of a wide range of xenobiotic 264 
agents including antibiotics, thus contributing to the emergence of MDR bacteria. 265 
The identified Q176K substitution in AcrB was found in strains already containing the 266 
EnvZ substitution and led to an additional 4-fold increase in the MIC of cefotaxime 267 
(Figure 5a). This substitution was only detected from planktonic cultures and had no 268 
additional impact on biofilm formation over that of the EnvZ R397H mutant. 269 
Based on the above, we hypothesised that the ‘first-step’ changes in MIC were due 270 
to alterations in expression of ompC and ompF following mutation of envZ. 271 
Subsequent substitution in AcrB, was responsible for altered coordination of 272 
cefotaxime by AcrB (Q176 is in the distal drug binding pocket of AcrB) and 273 
correspondingly lowered residence time of the antibiotic in the pocket, leading to 274 
increased efflux of this substrate. Changes in curli expression (due to loss of EnvZ-275 
mediated activation of OmpR), would account for the compromised biofilm formation 276 
phenotype we observed for these isolates. 277 
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We tested this hypothesis in a number of ways. First, we isolated RNA from 48-hour 278 
biofilms, grown in LB agar plates with no salt, formed by strains carrying the 279 
identified substitutions (cef-biofilm-M-D-S1 (EnvZ R397H) and cef-plank-L-S2 (EnvZ 280 
R397H/ AcrB Q176H)), as well as the WT strain as a control. We performed qRT-281 
PCR to measure ompC and ompF expression, using gyrB expression as our 282 
reference (Figure 5b). We observed a significant reduction in ompF expression in 283 
both the mutants as well as an overexpression of ompC indicating that the balance 284 
of porin expression had been altered as predicted (Figure 5b). To test whether the 285 
decrease in ompF led to reduced drug accumulation in the cells, we used a resazurin 286 
drug accumulation assay which confirmed that, both mutants show reduced 287 
accumulation of drugs inside the cell (Figure 5d). 288 
Additionally, we measured expression of the main curli subunits, csgA and csgB, and 289 
found that expression in the mutants was completely lost (Figure 5c). This explains 290 
the pale phenotype on CR and supports our hypothesis that loss of EnvZ function 291 
confers protection against cefotaxime, but at a cost to biofilm formation. 292 
We confirmed the specific phenotypic impacts of the two substitutions by creating 293 
mutants of the parent strain lacking acrB or envZ and complementing these with 294 
either wild-type or mutant alleles and determining the impacts on phenotypes (Figure 295 
5a). Deletion of envZ and complementation with the WT allele did not lead to any 296 
MIC changes for any of the antibiotics tested. However, complementation with the 297 
mutant pEnvZ R397H allele led to a significant increase in MICs of cefotaxime, 298 
chloramphenicol and tetracycline. Similarly, although complementation of the AcrB 299 
deletion strain with AcrB or AcrB Q176K did not have an impact on resistance, 300 
complementation of AcrB in a ΔAcrB/ ΔRamR background with the Q176K allele led 301 
to decreased susceptibility to cefotaxime, chloramphenicol and tetracycline, 302 
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replicating the phenotype of strains derived from the evolution experiments. These 303 
results confirm that the mutations identified are responsible for the resistance 304 
phenotypes observed after exposure to cefotaxime. 305 
Finally, we performed in silico modelling work to investigate the potential impact of 306 
the Q176K substitution on AcrB structure and substrate binding (Figure 4e-f). 307 
AutoDock VINA docking simulations were used, allowing for flexible side-chains. 308 
Analysis of cefotaxime docking, as well as docking of the control antibiotics, 309 
nitrocefin and cephalothin, to both the WT (Q176) and the mutant (Q176K), were 310 
based on experimental crystallographic studies (supplementary figure S1, a-b). The 311 
analysis focused on the distal binding pocket of chain B of AcrB from E.coli 312 
(4DX5.pdb) (27) corresponding to the “bound” or “tight” protomer conformation. We 313 
found that in both cases, Q176 and the mutant side chain, Q176K, participated in the 314 
coordination of cephalosporin molecules. However, the coordination was markedly 315 
different, between the WT and the mutant, and resulted in statistically significant 316 
reduction in the free energy of binding (ΔG) (Supplementary table S1). This supports 317 
the idea that the substitution might cause a reduction in the residence time for drugs 318 
in the pocket and as a result, increased efflux and decreased susceptibility. 319 
Novel mechanisms of azithromycin resistance 320 
Lineages exposed to azithromycin developed an 8-fold increase in azithromycin MIC 321 
(reaching the proposed epidemiological cut-off to define resistance in Salmonella 322 
(28)) before adapting further to have an MIC 16x higher than the parent (Figure 5f). 323 
When we sequenced the resistant strains, we identified two distinct amino acid 324 
substitutions. In the first population, there was an arginine 717 substitution to leucine 325 
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in AcrB and the mutants with highest MICs also had a threonine 18 substitution to 326 
proline in RamR.  327 
Interestingly, this substitution in AcrB is distinct from that observed after cefotaxime 328 
exposure, and in a different part of the protein. The distal binding pocket is predicted 329 
to control access of substrates into the pump, as well as participating in the 330 
coordination of high-molecular mass substrates, such as macrolides in the proximal 331 
binding pocket (29,30). This indicates that changes in different parts of AcrB confer 332 
resistance to different substrates.  333 
RamR is the transcriptional repressor of ramA, which is a global transcriptional 334 
activator that positively regulates the AcrAB-TolC pump production (31). The 335 
inactivation of ramR results in over-expression of RamA, consequently increasing 336 
pump expression and inducing an MDR phenotype (32). We observed that isolates 337 
with this substitution also acquired cross-resistance to cefotaxime, chloramphenicol, 338 
nalidixic acid, tetracycline and triclosan, all of which are AcrB substrates. 339 
Our hypothesis was that the R717L substitution in AcrB would result in increased 340 
efficiency of efflux of azithromycin and as a result, increased resistance. The 341 
additional RamR substitution would then result in over-expression of this mutant 342 
pump and explain the further increase in the MIC of azithromycin. To test this 343 
hypothesis, we extracted RNA from 48-hour old biofilms and we measured 344 
expression of acrB and ramA by q-RT-PCR, again using gyrB expression as our 345 
reference (Figure 5g). For both targets there was up-regulation in the mutants 346 
compared to the parent strain although expression levels of acrB in all cells were 347 
low; AcrB is primarily produced in growing cells so low levels of acrB mRNA was not 348 
unexpected. Intracellular drug accumulation was monitored as described above 349 
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using the resazurin method (Figure 5h). The R717L mutant alone did not show any 350 
changes in accumulation compared to the WT, suggesting the substitution does not 351 
impact export of this substrate. This supports the idea that this change improves 352 
access for larger substrates to the pump (such as azithromycin, Mr:749), which relies 353 
on the proximal drug binding vetting. However, this would not impact a small 354 
molecule like resazurin (Mr:229), which has been suggested to directly access the 355 
distal binding pocket, by bypassing the proximal pocket of the pump (30,33). 356 
Consistent with this idea was the observation of markedly reduced resazurin 357 
accumulation in the double mutant, where pump over-expression would be expected 358 
to reduce accumulation of a wide range of substrates and confer the typical efflux-359 
based MDR phenotype observed. 360 
To confirm the causative impact of these mutations, we used the same approach as 361 
for the cefotaxime mutations where we re-introduced mutant and wild-type alleles of 362 
acrB and ramR into mutants lacking these genes to observe the impact (Figure 5f). 363 
AcrB R717L introduction to the ΔacrB background led to increased resistance only 364 
against azithromycin, complementing perfectly the phenotype of the adapted and 365 
evolved strain carrying the AcrB R717L mutation.  RamR T18P introduction to the 366 
ΔramR background led to an additional increase in MICs of azithromycin, 367 
chloramphenicol, nalidixic acid and tetracycline, confirming the hypothesis that 368 
overexpression of the efflux pump leads to an MDR response. These results confirm 369 
that these are the mutations responsible for the resistant phenotypes observed after 370 
exposure to azithromycin.  371 
To investigate the impact of the R717L substitution on the structure and function of 372 
AcrB, we performed molecular docking of azithromycin and erythromycin 373 
(supplementary Figure S2, a-b) in the proximal binding site. The proximal binding 374 
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pocket is split into two distinct, yet overlapping macrolide binding sites, A and B.  Site 375 
A is known to be responsible for rifampicin binding, whereas, site B has been 376 
associated with erythromycin binding and is located deeper into the proximal pocket 377 
(30). 378 
We first docked  azithromycin in site B of the proximal binding pocket, producing a 379 
model structure, which closely matches the experimental structure of AcrB with 380 
erythromycin (3AOC.pbd, chain C, supplementary figure S2, a-b)(30). Our analysis 381 
indicated that R717 is located too far away to directly interact with the drug, making it 382 
unlikely for the observed coordination in site B to contribute to the observed 383 
phenotype. To investigate whether R717 participates in earlier stages of the 384 
substrate recognition pathway, we performed docking of azithromycin to site A, 385 
located in the front part of the proximal binding pocket (Figure 4g). This showed 386 
plausible coordination with direct involvement of R717, and also indicated a clear 387 
energetic advantage of the R717 WT over R717L. In fact, R717L led to a radically 388 
different coordination of azithromycin (Figure 4h, supplementary table S1), 389 
rationalising the observed MDR phenotype. 390 
Drug resistance in biofilms is stable once selected but costs to virulence and 391 
biofilm formation can be ameliorated by stress free passage  392 
We showed that control biofilms that have not been exposed to drugs rapidly 393 
adapted to form better biofilms during the experiment (Figure 1f). However, when 394 
these strains were tested for drug susceptibility, no changes were observed over 395 
time (Figure 6a). There was also no correlation between biofilm ability and 396 
antimicrobial susceptibility in these populations which were not exposed to any drugs 397 
(Figure 6b). This shows that making more biomass does not alone affect antibiotic 398 
susceptibility.  399 
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While we initially investigated whether biofilms have inherently altered susceptibility 400 
to antibiotics using conventional susceptibility testing, we also tested whether 401 
biofilms were more tolerant of drugs in context. To test whether biofilm-adapted 402 
strains have a viability advantage when treated with antibiotics, we grew biofilms on 403 
beads for 72 hours at 30oC, and then washed them and exposed them to a range of 404 
ciprofloxacin concentrations (Figure 6c). To determine the survival rate, we isolated 405 
and counted surviving cells. Survival was normalised against biofilms formed from 406 
each strain unexposed to drug. We tested: a planktonic isolate which had been 407 
exposed to ciprofloxacin (Cip-plank-L-S1), a control biofilm-adapted isolate not 408 
exposed to any drug (biofilm-control-L-S1) and an exposed, biofilm adapted isolate 409 
from the ciprofloxacin evolution experiment (Cip-biofilm-L-B-S3). The control biofilms 410 
made significantly more biomass than the drug exposed biofilms but demonstrated 411 
only a mild increase in survival to the drug treatment compared to the WT strain. 412 
Biofilms formed by the drug-exposed planktonic lineage (adapted and highly 413 
resistant to ciprofloxacin but with equivalent biofilm formation ability to the parent) 414 
had also a mild increase in survival compared to WT biofilms. Interestingly, only 415 
bacteria from the biofilm lineage exposed to ciprofloxacin exhibited a significant 416 
survival increase even though this strain was no more resistant (by MIC) than the 417 
planktonic mutant and made significantly less biofilm than the drug free control. This 418 
suggests that neither specific resistance to ciprofloxacin or the ability to make more 419 
biomass are enough to improve survival within a biofilm alone. To confirm these 420 
results, we grew biofilms on coverslips for 72 hours at 30oC, treated them with 3 421 
μg/mL ciprofloxacin for 90 minutes and carried out live/dead staining to visually 422 
characterise survival by fluorescence microscopy (Figure 6d). Our first observation 423 
was that, as expected, the different strains formed biofilms of variable density.  424 
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Survival was only obvious in the denser biofilm regions, where cells produced more 425 
biomass and significant numbers of surviving cells were only observed in the 426 
ciprofloxacin-exposed biofilm lineage. Visualisation of this biofilm showed denser 427 
clusters of cells than the WT or biofilm-adapted lineage biofilms. Whilst the overall 428 
level of biomass was not as high as drug free adapted controls for this strain, the 429 
results suggest that a combination of improved biofilm formation and stress 430 
adaptation are essential for biofilm viability and survival. 431 
To test whether drug adaptation influences pathogenicity, we selected isolates from 432 
different exposures and tested their virulence in the Galleria mellonella infection 433 
model (Figure 6e, bar chart). Larvae were injected with strains representing different 434 
biofilm and resistance phenotypes. Un-injected larvae as well as PBS controls were 435 
included as appropriate and the wild type strain (14028S) was used as a reference. 436 
In parallel we measured biofilm formation for all cultures used to inoculate larvae 437 
using both the CV (Figure 6e, overlaid line graph on the right axis) and the CR 438 
assay. We observed that strains with increased biofilm ability were the least 439 
infectious, whereas isolates with weaker biofilm phenotypes were most pathogenic. 440 
For example, biofilm-control-L-S1, which is a drug free control, biofilm-adapted 441 
strain, caused the least deaths with a 95% survival rate. In comparison, Cip-biofilm-442 
M-B-S2, which is a drug-resistant but low-biofilm-forming strain, killed 50% of the 443 
larvae. Hence, adaptation to the drug exposure had no obvious advantage for 444 
pathogenicity. Our data suggests a strong correlation between pathogenicity and 445 
biofilm formation but no association with resistance. 446 
To test the stability of the phenotypes obtained during the course of the evolution 447 
experiments, we selected resistant strains to the previous antibiotic exposures with 448 
low and high biofilm forming abilities (see materials and methods) and put them 449 
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through a 24-hour passage, accelerated biofilm evolution experiment (Figure 6, f-i). 450 
This was run for 10 days with passages every 24 hours without any antibiotics 451 
present, to test whether the resistance and biofilm patterns change over time without 452 
any selection. From each population, we isolated single strains and phenotyped 453 
them for their biofilm ability and their susceptibility against the same panel of 454 
antibiotics we used previously (see materials and methods). We observed that 455 
resistance remained stable for most antibiotics (Figure 6f), while the overall ability of 456 
the tested strains to form biofilms improved significantly over time (p<0.04, Figure 457 
6g). We also looked individually at the strains with initially low biofilm ability and 458 
decreased susceptibility (azi-biofilm-M-B-S2, cef-biofilm-L-A-S1) and we observed 459 
that stability of resistance is highly dependent on the nature of the stress. The MIC of 460 
azithromycin did not significantly change over time for the azithromycin resistant 461 
strain (Figure 6h, orange line), whereas the initially cefotaxime resistant strain 462 
exhibited significantly reduced susceptibility by the end of the accelerated 463 
experiment (Figure 6i, purple line). In both cases, the biofilm formation of the strains 464 
was recovered (Figure 6, h-i).  465 
  466 
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Discussion 467 
To develop new antimicrobial strategies, it is important that we understand the 468 
genetic mechanisms responsible for bacterial resistance in relevant contexts. 469 
Although the evolution of antimicrobial resistance is often studied, previous work has 470 
largely focused on planktonic cells and not bacterial biofilms. While it is commonly 471 
accepted that biofilms are inherently highly drug resistant, surprisingly little work 472 
explores how biofilms evolve in response to antimicrobial stress. One recent report 473 
showed that Acinetobacter biofilms do adapt to sub-lethal exposure to ciprofloxacin 474 
and that mechanisms of resistance were distinct to those seen in planktonic controls 475 
(34). Here we address this question using Salmonella biofilms as a model system 476 
with multiple drugs. 477 
The intrinsic resistance of biofilms to antimicrobials has been attributed to both 478 
unique structural characteristics of biofilms but also the wide range of growth states 479 
of cells present within biofilms, including dormant or persister cells (35–39). We 480 
investigated whether these already resistant communities evolve and adapt further 481 
when exposed to sub-inhibitory drug stress. We found that biofilms are highly 482 
sensitive to sub-inhibitory exposure to antibiotics, which rapidly selected for changes 483 
in the populations. Different stresses selected distinct patterns of adaptation, some 484 
of which were unique to the biofilm communities. There was no common response to 485 
all three drugs tested, which strongly suggests that there is not a common or generic 486 
mechanism for antimicrobial resistance seen in biofilms but instead adaptation highly 487 
depends on the nature of the stress.  488 
When cells were exposed to azithromycin or cefotaxime, both planktonic and biofilm 489 
populations became resistant not only to the selective drug but also to several 490 
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different antibiotics, indicating mechanisms conferring MDR. Strikingly, both 491 
azithromycin and cefotaxime selected for highly-resistant populations, but also with a 492 
marked attenuation of biofilm formation. Lineages exposed to ciprofloxacin were able 493 
to improve biofilm formation over time although this was delayed compared to control 494 
biofilms. The ciprofloxacin results are consistent with a recent observation from 495 
Acinetobacter biofilms, where biofilm formation was not compromised after exposure 496 
to the drug (34). It is clear from our results that selection of resistance within a biofilm 497 
can have a major impact on important phenotypes that impact on bacterial fitness 498 
and survival in the real world. 499 
To determine the mechanisms underlying susceptibility, we sequenced more than 500 
100 strains covering the different exposures and time points and demonstrating a 501 
range of distinct susceptibility and biofilm phenotypes. Azithromycin exposure 502 
selected for the same mutations (changes in AcrB and RamR) in independent 503 
lineages, and these emerged in a step-wise manner over the course of the evolution 504 
experiment. Similarly, exposure to cefotaxime selected for mutants with altered AcrB 505 
and EnvZ, with the same substitution within EnvZ observed in independent lineages. 506 
The primary aim of this work was to identify mechanisms rather than the detailed 507 
evolutionary dynamics of selection, however the presence of identical substitutions in 508 
multiple lineages is strong evidence for the importance of these changes. 509 
Ciprofloxacin exposure selected for a wider variety of mutations with much more 510 
variation in phenotypes indicating multiple paths of evolution and resistance. The 511 
difference between the drugs is likely to reflect the mechanisms of action and 512 
resistance; there are multiple known chromosomal mechanisms of ciprofloxacin 513 
resistance (including target site changes, porin loss, efflux) whereas high-level 514 
resistance to cefotaxime and azithromycin is often a result of acquisition of specific 515 
All rights reserved. No reuse allowed without permission. 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/605212doi: bioRxiv preprint first posted online Apr. 10, 2019; 
 23 
 
enzymes. In this closed system, acquisition of DNA is not possible, so cells are 516 
constrained to mutation of the core genome to generate resistant mutants. This 517 
hypothesis was supported by analysis of the mechanisms of resistance. 518 
After analysing the sequencing results, we were able to identify novel mechanisms of 519 
resistance against cefotaxime and azithromycin respectively, which we then 520 
confirmed experimentally.  521 
We showed that strains exposed to cefotaxime demonstrated a two-step selection of 522 
resistance with an initial four-fold rise in cefotaxime MIC, followed by an eight-fold 523 
increase. This was linked to an initial R397H substitution in the EnvZ protein followed 524 
by an additional Q176K genetic substitution in AcrB. We showed that the EnvZ 525 
R397H substitution alters the balance of porin production with down-regulation of the 526 
major outer membrane pore, OmpF and up-regulation of the narrow outer membrane 527 
pore, OmpC. EnvZ controls activity of OmpR, which is known to control the balance 528 
of porin production as well as biofilm formation under low medium osmolarity 529 
conditions (17,40). OmpF is well characterised as an entry point for β-lactams due to 530 
the molecules’ physiochemical properties, which makes entry possible through this 531 
porin which has a larger pore size than OmpC (41,42). We showed that with OmpF 532 
expression repressed, the cells are less permeable, leading to reduced levels of the 533 
antibiotic in the cell and as a result decreased susceptibility. Whilst the EnvZ 534 
substitution was selected in both planktonic and biofilm cultures only planktonic 535 
cultures acquired the additional Q176K AcrB substitution, leading to even further 536 
reduced drug accumulation and as a result, decreased susceptibility. To date,  the 537 
exact binding pocket responsible for recognition of cephalosporins, and β-lactams in 538 
general, remains debatable with evidence pointing either to the proximal or the distal 539 
binding pocket (25,43,44). Here, we showed that Q176K substitution is located in a 540 
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critically important position within the distal binding pocket of the protein, altering 541 
significantly the binding dynamics of the pocket towards cephalosporins. We 542 
hypothesise that this may lead to altered residence time in the pocket and result in 543 
the observed macroscopic MDR effect. Significantly, our results are consistent with 544 
prior data showing that Q176 is involved in substrate transport and coordination of 545 
the chromogenic cephalosporin antibiotic nitrocefin in both docking and MD 546 
simulation (25,29,45). Intriguingly, the orientation of cefotaxime in the binding pocket 547 
was found to differ significantly from that of nitrocefin and cephalothin suggesting 548 
multiple modes of β-lactam binding may exist within the distal binding pocket of AcrB 549 
(Supplementary Figure S1, a-b, d). 550 
Populations exposed to azithromycin also demonstrated a two-step selection, quickly 551 
developing resistance to the drug with an 8-fold followed by a 16-fold increase in 552 
azithromycin MIC. These changes were linked to two distinct amino acid 553 
substitutions; AcrB R717L and RamR T18P. The AcrB substitution is located in the 554 
proximal binding pocket, which is part of the principal drug entry and coordination 555 
pathway for high molecular mass drugs and is predicted to impact substrate entry to 556 
the pump. A role for R717 in the substrate pathway has previously been proposed 557 
(29) and also shown to participate in the coordination of the related antibiotic, 558 
rifampicin in at least one experimental structure (30). Docking of azithromycin into 559 
the macrolide site A and B of the experimental structures, revealed that the R717 is 560 
located far from the canonical site B, which is associated with erythromycin binding. 561 
Therefore, this residue is more likely to participate in the earlier stages of the 562 
substrate pathway in site A of the proximal pocket. Consistent with this interpretation, 563 
we observed that the top docking pose of the azithromycin site A of the proximal 564 
pocket brings it in direct contact with the R717 and as a result affected by the R717 565 
All rights reserved. No reuse allowed without permission. 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/605212doi: bioRxiv preprint first posted online Apr. 10, 2019; 
 25 
 
substitution. This makes the pump more effective at exporting azithromycin out of the 566 
cells and as a result, the population more resistant. The second substitution in RamR 567 
resulted in the upregulation of this already “upgraded” AcrAB pump, leading to a 16x 568 
rise in azithromycin MIC.  569 
A small number of substitutions within AcrB have been identified and predicted to 570 
change affinity for different drugs in the past (46). The substitutions identified in this 571 
study have not been previously characterised for their role in resistance, which we 572 
did here for the first time, providing strong genetic, phenotypic and structural 573 
evidence for their functional impacts. 574 
Both the mechanisms of resistance identified against azithromycin and cefotaxime 575 
directly affect both membrane permeability and efflux activity of the cells. The nature 576 
of these substitutions leads to cross-resistant phenotypes as accumulation of many 577 
drugs is compromised by alterations of general porins and AcrAB. This is of critical 578 
importance as exposure to a single drug can select for multi-drug resistant 579 
populations with health-threatening implications.  580 
We did however identify clear trade-offs between drug resistance and biofilm 581 
formation. Although previous studies have associated exposure to sub-inhibitory 582 
concentrations of azithromycin and cefotaxime with inhibition of biofilm formation 583 
(47,48), the mechanisms identified in this study have not, to the best of our 584 
knowledge, been associated with these antibiotics before. Although we showed that 585 
biofilms respond and adapt to antibiotic stresses, we observed that this adaptation is 586 
driven by the need to survive exposure to the drug and was not linked to biomass 587 
production. Control biofilms passaged without stress made much larger biofilms over 588 
time, but these improved biofilm forming lineages did not become more drug 589 
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resistant. To explore this surprising observation further, we grew biofilms of selected 590 
strains representing a variety of biofilm formation and resistance phenotypes and 591 
tested their ability to survive exposure to increasing ciprofloxacin concentrations. We 592 
observed that only biofilms which had been exposed to ciprofloxacin were 593 
significantly harder to kill. This reflects their possession of both a robust community 594 
structure and drug-specific resistance mutations that makes them fitter in the specific 595 
environment. Neither strains with increased resistance to ciprofloxacin but normal 596 
biofilm capacity, nor those with normal drug sensitivity but increased biofilm capacity, 597 
demonstrated a significant benefit when treated with ciprofloxacin. Based on these 598 
results, we hypothesise that producing more biomass is not necessarily the best 599 
solution to survive antibiotic exposure. Highly resistant biofilms may be more likely to 600 
result from a combination of both structural and drug specific mechanisms. 601 
Interestingly we did not identify mutations in pathways previously proposed to 602 
contribute to persister cell formation, suggesting that these were not important in 603 
adaption to the drug exposures in our experimental setup.  604 
Biofilms play a crucial role in chronic infections and our observations suggested an 605 
obvious fitness advantage of adapted biofilms over unexposed biofilm populations in 606 
terms of drug resistance. To see if this impacts virulence we investigated the 607 
pathogenicity of strains with different resistance and biofilm profiles, using the 608 
Galleria mellonella infection model. We observed that mutations that rendered the 609 
bacteria resistant to drugs had no significant impact on pathogenicity. However, the 610 
biofilm ability of the strains was negatively correlated with pathogenicity, with strains 611 
forming least biofilm being most virulent resulting in the lowest survival rates.  612 
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Having characterised a number of biofilm-related resistant phenotypes, we estimated 613 
their stability in the absence of drug selective pressure using an accelerated biofilm 614 
evolution experiment. Strains that had been exposed to ciprofloxacin and 615 
azithromycin maintained their resistance profiles over extended passaging but 616 
formed better biofilms. In contrast, cefotaxime exposed populations lost their 617 
acquired resistance after a few passages whilst they became better biofilm formers. 618 
This indicates that although stability of resistance is highly influenced by the nature 619 
of the antimicrobial stress, bacteria can quickly adapt to a more sessile, community-620 
orientated lifestyle in the absence of drug. Analysis of azithromycin-exposed 621 
populations which had improved their biofilm ability identified loss-of-function 622 
mutations in cyclic di-GMP phosphodiesterase, YjcC. This is unsurprising as cyclic 623 
di-GMP is well known for its role in biofilm formation in several organisms including 624 
Salmonella, which harbours 12 proteins with GGDEF and 14 proteins with EAL 625 
domains (49,50).  626 
In conclusion we demonstrate here that biofilms are highly sensitive to stress from 627 
low levels of antibiotics, rapidly adapt to drug pressure and that mechanisms of 628 
resistance can incur costs to other important phenotypes. Using similar approaches 629 
to those outlined here will help understand the impacts of drug exposure on biofilms 630 
in many contexts. This can help inform how best to use antimicrobials and predict 631 
how biofilms will respond to different stresses.   632 
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Materials and methods 633 
Biofilm adaptation and evolution model 634 
Salmonella enterica serovar Typhimurium 14028S was used as the parent strain to 635 
initiate all biofilm experiments in this study. This strain has been used as a model for 636 
S. Typhimurium biofilm studies by many groups including our own and has a fully 637 
closed and annotated reference genome (Accession number: CP001363). To study 638 
adaptation and evolution of Salmonella biofilms, we adapted a model described by 639 
the Cooper group (11). Bacteria were grown on 6 mm soda lime glass beads (Sigma, 640 
Z265950-1EA) for 72 hours in Lysogeny Broth (LB) with no salt. They were 641 
incubated in glass universal tubes containing 5 mL of the medium in horizontal 642 
position, with mild rocking at 40 rpm, at 30 oC. For each passage, the beads were 643 
washed in PBS and transferred into fresh media with new sterile beads. The 644 
experiment was carried out at the presence of three clinically-important antibiotics; 645 
azithromycin, cefotaxime and ciprofloxacin at a final concentration of 10 μg/mL, 646 
0.062 μg/mL and 0.015 μg/mL respectively. Eight independent lineages were 647 
included per exposure; four drug-exposed biofilm lineages, two drug-exposed 648 
planktonic cultures and two unexposed, bead-only control lineages. In each tube, 649 
three initially sterile beads were used, one to be transferred to the next lineage, one 650 
to be stored, and one from which cells were recovered for phenotyping. For storage, 651 
one bead per passage was frozen in 20 % glycerol. For phenotyping, the cells were 652 
isolated from the beads by vortexing in PBS for 30 seconds and then grown 653 
overnight in 1 mL of LB broth, before being stored in chronological order in deep-well 654 
plates in glycerol. The experiments were completed after 250 generations (17 655 
passages) for the azithromycin and cefotaxime exposure and after 350 generations 656 
(24 passages) for the ciprofloxacin exposure. Populations from an early (first 657 
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passage), middle (half way point lineage) and late (final passage) time point were 658 
chosen for study and from each, three single colonies were isolated, sub-cultured 659 
and stored in 20% glycerol. These single-cell isolates, and their parent populations 660 
were stored in deep-well 96-well plates and used for phenotyping by replicating the 661 
bacteria onto appropriate media to test for fitness, biofilm ability, morphology and 662 
susceptibility (replication used ‘QRep 96 Pin Replicators’, Molecular devices X5054). 663 
Figure 1 shows an overview of the experimental setup and phenotyping procedure. 664 
Model optimisation  665 
To determine the optimum culture conditions for achieving the greatest cell carriage 666 
of S. Typhimurium 14028S biofilms on the glass beads, biofilms were grown in 5 mL 667 
LB without salt on 6 mm glass beads at four standard microbiological incubation 668 
temperatures: 25 °C, 30 °C, 37 °C and 40 °C. The cell counts on beads grown at 669 
each temperature was determined every 24 hours for 96 hours. Biofilms were 670 
washed in 1 mL PBS and harvested via vortexing for 30 seconds. The harvested 671 
cells were serially diluted in a microtiter tray containing 180 µL PBS and 5 µL was 672 
spotted onto a square LB agar plate. The number of colony forming units was 673 
calculated and the incubation conditions yielding the greatest amount of cells was 674 
determined. 675 
Crystal violet assay (CV) 676 
To measure biofilm formation, selected strains were grown overnight in LB broth and 677 
then diluted into 200 μL of LB-NaCl to give an OD of 0.01 in microtiter plates. The 678 
plates were incubated at 30 oC for 48 hours, covered in gas-permeable seals before 679 
wells were emptied and vigorously rinsed with water before staining. For staining, 680 
200 μL of 0.1% CV was added to each well and incubated for 15 minutes at room 681 
temperature. The crystal violet dye was then removed, and the wells were rinsed 682 
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with water. The dye bound to the cells was then dissolved in 70% ethanol and the 683 
absorbance was measured at 590 nm in a plate reader (FLUOStar Omega, BMG 684 
Labtech).  685 
Biofilm morphology 686 
To visually assess biofilms morphology, we replicated isolates stored in 96 deep-well 687 
plates on 1% agar LB-NaCl plates, supplemented with 40 μg/mL Congo red (CR) 688 
dye. The strains of interest were diluted to a final OD of 0.01 in a microtiter plate and 689 
were then printed on the Congo red plates. The plates were incubated for 48 hours 690 
at 30 oC before being photographed to capture colony morphology.   691 
Antimicrobial susceptibility testing 692 
To determine the minimum inhibition concentrations of antimicrobials against strains 693 
of interest, we used the broth microdilution method (51) and the agar dilution method 694 
(13), following the EUCAST guidelines. In both cases, Mueller-Hinton broth or agar 695 
was used. Changes of less than two dilutions were not considered significant. 696 
Molecular Modelling and Antibiotic Docking 697 
For docking analysis, protein and ligand PDB files were first converted to PDBqt 698 
format using Raccoon (52). AutoDock Vina (53) was used for unbiased flexible 699 
docking simulations of ligands on protein structures using an optimal box size, 700 
estimated according to the radius of giration of the ligands (grid-point spacing of 1 701 
Å), centred on the predicted binding sites (supplementary table S1). The PyMOL 702 
Molecular Graphics System, Version 2.0 Schrödinger, LLC. was used to visualize the 703 
results. Formore information on model validation see supplementary materials.  704 
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Extraction of DNA 705 
To extract genomic DNA for sequencing, selected strains were grown O/N in a 96-706 
deep-well plate in LB, at a final volume of 1.5 mL. Cells were recovered by 707 
centrifugation at 3,500 g and were resuspended in 100 μL of lysis buffer (5 μg/mL 708 
lysozyme, 0.1 mg/mL RNAse in Tris-EDTA, pH 8) per well. The resuspended cells 709 
were then transferred in a new semi-skirted, low-bind PCR plate, secured with an 710 
adhesive seal and incubated at 37 oC, 1600 rpm for 25 minutes. 10 μL of a lysis 711 
additive buffer (5% SDS, 1 mg/mL proteinase K, 1 mg/mL RNAse in Tris-EDTA, pH 712 
8) was added in each well and the plate was sealed with PCR strip lids before being 713 
incubated at 65 oC, 1600 rpm for 25 minutes. The plate was briefly centrifuged and 714 
100 μL were moved to a new PCR plate. For the DNA isolation, 50 μL of DNA-715 
binding magnetic beads (KAPA Pure beads, Roche diagnostics) were added in each 716 
well and were incubated at room temperature for 5 minutes. The plate was then 717 
placed on a magnetic base and the supernatant was removed by pipetting. The 718 
beads were washed three times with 80% freshly-prepared ethanol. After removing 719 
the last wash, the beads were left to dry for 2 minutes before eluting the DNA. For 720 
the DNA elution, the plate was removed from the magnetic apparatus and 50 μL of 721 
Tris-Cl were added to each well. The beads were pulled using the magnetic 722 
apparatus and the isolated DNA was transferred to a new PCR plate. DNA 723 
concentration was determined using the Qubit ds DNA HS Assay kit (Q32851) 724 
following the manufacturer’s instructions.  725 
Whole Genome sequencing  726 
Genomic DNA was normalised to 0.5 ng/µL with 10mM Tris-HCl. 0.9 µL of TD 727 
Tagment DNA Buffer (Illumina Catalogue No. 15027866) was mixed with 0.09 µL 728 
TDE1, Tagment DNA Enzyme (Illumina Catalogue No. 15027865) and 2.01 µL PCR 729 
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grade water in a master mix and 3ul added to a chilled 96 well plate. 2 µL of 730 
normalised DNA (1ng total) was mixed with the 3 µL of the tagmentation mix and 731 
heated to 55 ⁰C for 10 minutes in a PCR block. A PCR master mix was made up 732 
using 4 ul kapa2G buffer, 0.4 µL dNTP’s, 0.08 µL Polymerase and 4.52 µL PCR 733 
grade water, contained in the Kap2G Robust PCR kit (Sigma Catalogue No. 734 
KK5005) per sample and 11 µL added to each well need to be used in a 96-well 735 
plate. 2 µL of each P7 and P5 of Nextera XT Index Kit v2 index primers (Illumina 736 
Catalogue No. FC-131-2001 to 2004) were added to each well. Finally, the 5 µL 737 
Tagmentation mix was added and mixed. The PCR was run with 72 ⁰C for 3 minutes, 738 
95 ⁰C for 1 minute, 14 cycles of 95 ⁰C for 10 seconds, 55 ⁰C for 20 seconds and 72 739 
⁰C for 3 minutes. Following the PCR reaction, the libraries were quantified using the 740 
Quant-iT dsDNA Assay Kit, high sensitivity kit (Catalogue No. 10164582) and run on 741 
a FLUOstar Optima plate reader. Libraries were pooled following quantification in 742 
equal quantities. The final pool was double-spri size selected between 0.5 and 0.7X 743 
bead volumes using KAPA Pure Beads (Roche Catalogue No. 07983298001). The 744 
final pool was quantified on a Qubit 3.0 instrument and run on a High Sensitivity 745 
D1000 ScreenTape (Agilent Catalogue No. 5067-5579) using the Agilent Tapestation 746 
4200 to calculate the final library pool molarity. The pool was run at a final 747 
concentration of 1.8 pM on an Illumina Nextseq500 instrument using a Mid Output 748 
Flowcell (NSQ® 500 Mid Output KT v2(300 CYS) Illumina Catalogue FC-404-2003) 749 
and 15 pM on a Illumina MiSeq instrument. Illumina recommended denaturation and 750 
loading recommendations which included a 1% PhiX spike in (PhiX Control v3 751 
Illumina Catalogue FC-110-3001). Whole genome sequencing data has been 752 
deposited in the Sequence Read Archive under PRJNA529870.  753 
  754 
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Bioinformatics 755 
Sequence reads from the sequencer were uploaded on to virtual machines provided 756 
by the MRC CLIMB (Cloud Infrastructure for Microbial Bioinformatics) project using 757 
BaseMount (54). Quality filtering of the sequence reads was performed using 758 
Trimmomatic (version 3.5) with default parameters (55). Trimmomatic’s Illuminaclip 759 
function was used to remove the Illumina adapters. The trimmed reads were then 760 
assembled into contigs using SPAdes version 3.11.1 using default parameters (56).  761 
To determine single nucleotide polymorphisms (SNPs) between the de novo 762 
assembled Salmonella genomes and the parent genome. Snippy version 3.1 was 763 
used using parameters recommended in (https://github.com/tseemann/snippy). The 764 
Snippy-core from the Snippy tool box was used to determine the core SNPs. The full 765 
genome alignment output by Snippy-core was used in subsequent phylogenetic 766 
analyses, after removal of the published reference sequence (accession number 767 
CP001363). All 4870267 sites were included in the analysis to avoid ascertainment 768 
bias (57).  A whole-genome phylogenetic tree was then inferred from the 63 769 
sequences under the model HKY+G implemented in iq-tree (58). For the individual 770 
population analyses the control sequences were removed, the trees were estimated 771 
with iq-tree, using the HKY+G evolutionary model. All trees were arbitrarily rooted at 772 
the cultivated parental sequence 14028S for visualisation purposes, and were 773 
plotted with ggtree for R (59). Branch lengths are given in units of substitutions/site.  774 
Preparation of RNA samples for q-RT PCR 775 
RNA from biofilms was isolated using the SV Total RNA Isolation System kit 776 
(Promega). RNA was extracted from the WT (14028S), cef-biofilm-M-D-S1 777 
(EnvZR397H), cef-plank-L-S2 (EnvZR397H/ AcrB Q176K), azi-biofilm-E-B-S2 (AcrB 778 
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R717L) and azi-biofilm-M-B-S1(AcrB R717L/ RamR T18P) strains. These were 779 
grown O/N at 37 oC in LB and then spotted on LB-NaCl agar plates and were grown 780 
for 48 hours at 30 oC. Cells from each spot were then resuspended in 100 μL TE 781 
containing 50 mg/mL lysozyme and were homogenised by vortexing. 75 μL RNA 782 
Lysis Buffer (Promega kit), followed by 350 μL RNA Dilution Buffer (Promega kit) 783 
were added to the cell suspensions, which were then mixed by inversion. Samples 784 
were incubated at 70 °C for 3 minutes and centrifuged at 13,000 g for 10 minutes. 785 
The supernatant was mixed with 200 μL 95 % ethanol and was then loaded on to the 786 
spin columns provided by the kit. The columns were washed with 600 μL RNA Wash 787 
Solution. DNAse mix was prepared following the Promega kit protocol and 50 μL 788 
were directly added on the column membrane. After a 30 minutes incubation, 200 μL 789 
DNAse Stop Solution was added and samples were centrifuged for 30 seconds. 790 
Columns were washed with 600 μL RNA Wash Solution followed by 250 μL RNA 791 
Wash Solution, and then centrifuged again for 1 minute to dry. RNA was eluted using 792 
100 μL of nuclease-free water. RNA quantification was performed using the Qubit 793 
RNA High Sensitivity Assay kit (Q32852). 794 
Quantitative Real-Time PCR (q-RT PCR) 795 
To determine expression levels of ompC/F, csgA/B and ramA, we performed q-RT 796 
PCR using the Luna Universal One-Step RT-qPCR Kit from NEB (E3005), using the 797 
Applied BiosystemsΤΜ 7500 Real-Time PCR system. The primers used for the q-RT 798 
PCR are listed in Table 2. Efficiency of the primers was calculated by generation of 799 
calibration curves for each primer pair on serially diluted DNA samples. The R2 of the 800 
calibration curves calibrated was ≥0.98 for all the primer pairs used in this study.  801 
RNA at a final amount of 50-100 ng was added to 10 μL final volume PCR reactions, 802 
mixed with 400 nM of each primer. The cycle parameters were as follows: 10 803 
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minutes at 55 oC (reverse transcription step), 1-minute denaturation at 95 oC and 40 804 
cycles of 10 seconds at 95 oC and 1 minute at 60 oC.  805 
For each sample, two technical replicates from two biological replicates each were 806 
included (four in total) per reaction. Controls with no reverse transcriptase were also 807 
included for each RNA sample to eliminate DNA contamination. 808 
To calculate expression levels, expression fold change was calculated using gyrB 809 
expression as a reference. The relative expression was determined by calculating 810 
the logarithmic base 2 of the difference between gyrB gene expression and target 811 
gene expression per sample.  812 
Viability of cells within biofilms 813 
To determine the viability of cells within a biofilm, two approaches were used. The 814 
first approach involved growing biofilms on glass beads for 72 hours. They were 815 
washed in PBS to remove planktonic cells and were then challenged with different 816 
concentrations of ciprofloxacin (0, 0.03, 0.3, 3 μg/mL) for 90 minutes. Beads were 817 
washed again in PBS to remove any antibiotic and transferred into 1 mL of PBS 818 
solution to an Eppendorf tube, where they were vigorously vortexed for 1 minute. 819 
The cells recovered in PBS were serial diluted and spotted onto LB plates for CFU 820 
counting the next day. For the second approach, we grew biofilms on glass slides for 821 
72 hours. The slides were washed in PBS and were challenged with ciprofloxacin (3 822 
μg/mL) for 90 minutes. They were washed in PBS and stained with a solution of 12 823 
μM propidium iodide (PI) and 300 nM of SYTO 9 for 30 minutes. They were washed 824 
in PBS and soaked in 70% ethanol to kill the cells before they were transferred to a 825 
slide for microscopy. Fluorescence microscopy was performed in a Zeiss Axio 826 
Imager M2. 827 
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Galleria Infection model 828 
To test the pathogenicity of different mutants, we used the Galleria mellonella larvae 829 
infection model. Wax worms were obtained from livefoods.co.uk. Similarly-sized 830 
larvae with no signs of pupation or melanisation were chosen for injection. An initial 831 
experiment was performed to calculate the infectious dose of S. Typhimurium 832 
14028S in G. mellonella, which determined that an inoculation with approximately 833 
20,000 CFU resulted in death of approximately half of 10 larvae after 72 hours. Once 834 
this had been determined, overnight cultures of each strain were diluted in PBS to 835 
replicate this inoculum concentration and 10 μL of this were injected into the second 836 
hindmost left proleg of ten larvae. To check the concentration of each inoculum, 100 837 
μL of each dilution were also plated onto LB agar and incubated overnight at 37°C. 838 
CFUs were counted the next day and the inoculum concentration was confirmed. 839 
Controls included in this experiment included larvae injected with PBS only and un-840 
injected larvae. All larvae were incubated at 37 °C and were checked three times a 841 
day for 3 days to record the survival rate. The experiment was repeated on three 842 
independent occasions, with 10 larvae randomly allocated per strain in each 843 
experiment. Survival was calculated as the percentage of surviving larvae 48 hours 844 
after injection (Figure 6, e).  845 
Cellular permeability assays 846 
To detect differences in cellular permeability to drugs between mutants, the 847 
resazurin accumulation assay was used. The strains of interest were grown to 848 
exponential phase, using a 1:100 inoculum from overnight cultures. The cells were 849 
washed and resuspended in PBS normalising for cell density and they were mixed 850 
with resazurin to a final volume of 100 μL (to give 10 μg/mL) in round-bottom 851 
microtiter plates. Fluorescence was measured in the Omega FLUOstar plate reader 852 
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at excitation 544 nm and emission of 590 nm. Five replicates were included per 853 
strain and resazurin-only reactions were used as controls. The assay was repeated 854 
at least twice with reproducible results observed each time.  855 
Accelerated evolution experiments 856 
To test the phenotypic stability of strains recovered from the initial evolution 857 
experiments, we performed an accelerated evolution experiment using six strains 858 
representing a spectrum of biofilm forming capacities and drug resistance phenotypes 859 
(WT, control-biofilm-L-S1, azi-biofilm-M-B-S2, azi-biofilm-M-B-S3, cef-biofilm-L-A-S1, 860 
cip-biofilm-M-B-S2, cip-biofilm-L-B-S3). The strains were resuscitated from storage by 861 
a 24-hour incubation at 37 °C in LB broth. After incubation, 50 µL of broth was added 862 
to 5 mL of LB broth (without salt) containing three sterile glass beads and incubated 863 
for 24 hours at 30 °C, until a biofilm was formed. Each bead was then washed in 1 mL 864 
PBS to remove planktonic and loosely adherent cells. Two beads were stored in deep-865 
well plates containing 20 % glycerol for archiving and phenotyping. The third bead was 866 
transferred to another tube of LB broth (without salt) containing three sterile glass 867 
beads and passaged. This was repeated for ten passages, storing beads at each 868 
timepoint. 869 
Upon completion of ten passages, populations were recovered from passage five, 870 
passage ten and the parental population for each mutant. From each population, 871 
single colonies were picked after streaking out each population on LB agar and 872 
incubating for 24 hours at 37 °C. Three colonies from each population were then 873 
subcultured in LB broth. A population and three isolates from the start, middle and end 874 
of the passage series were isolated and phenotyped for each mutant. Biofilm formation 875 
was evaluated using the Congo Red and Crystal Violet assays. The agar dilution 876 
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methodology was used to assess the minimum inhibitory concentrations of antibiotics. 877 
The average of the fold MIC change per antibiotic for all strains was calculated and 878 
plotted against time. The average of biofilm formation, as determined by the crystal 879 
violet assay, was calculated for all the strains per timepoint. 880 
Statistical analysis 881 
Biofilm forming ability was compared between strains or time points using linear mixed 882 
models, with a random intercept of lineage where more than one lineage was included 883 
for each strain or condition (Figures 1f and 6g).   884 
Surviving cell counts were compared between strains using a linear mixed model with 885 
a Poisson response, with random intercept of replicate, fixed effects of exposure, the 886 
interaction between strain and exposure, and offset by the log of the average number 887 
of cells counted in the ‘unexposed’ condition for each strain.  Modelled means in each 888 
exposure were then normalised by the average number of cells across all unexposed 889 
conditions for plotting, such that the values shown represent the estimated proportion 890 
of cells that would survive each exposure for each strain (Figure 6c). All error bars 891 
reflect estimates +- one standard error.  892 
Strains and genetic manipulations 893 
Escherichia coli DH10b was used as a host for all cloning procedures. 894 
Transformations of E. coli were carried out by heat shock of chemically competent E. 895 
coli cells. Transformation of Salmonella was carried out by electroporation. 896 
Salmonella electrocompetent cells were prepared as follows: Salmonella cells were 897 
grown to early exponential phase (OD600nm 0.2-0.3) in 50 mL of 2x YT, using a 1:100 898 
inoculum from an overnight culture. The cells were centrifuged and washed once 899 
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with filter sterilised ice-cold water. They were left to incubate on ice for 1 hour before 900 
they were pelleted at 3,000 g for 15 minutes. The cell pellet was resuspended in 1 901 
mL of 10% filter-sterilised glycerol and 100 μL were used per transformation.  902 
To create gene deletion mutants, we used the λ-red-based, gene doctoring 903 
technique previously described in (60). For each deletion, two homologous regions 904 
upstream and downstream of the genes of interest were amplified by PCR and were 905 
cloned in MCS1 and MCS2 of the pDOC-K vector. The homologous regions were 906 
300-400 bp in length and were designed to include the first and last 10 codons of the 907 
gene to be deleted, to avoid any pleiotropic effects after deletion. For acrB and ramR 908 
deletions, the upstream homologous regions were cloned EcoRI/ BamHI in MCS1 909 
and the downstream ones as XhoI/ NheI in MCS2 of pDOC-K. For the envZ deletion, 910 
the upstream homologous region was cloned EcoRI/ BamHI in MCS1 and the 911 
downstream one as XhoI/ SpeI in MCS2. 912 
For complementation of mutated genes, chromosomal integrations were created to 913 
insert wild-type copies or mutated versions of genes of interest. This used a 914 
modification of the gene doctoring system described above. pDOC-K was modified 915 
to be used to deliver chromosomal gene integrations to the neutral intragenic region 916 
downstream of glms. This chromosomal insertion site was proven to be neutral 917 
through insertion of the reporter gene lacZ, where the mutant had no significant 918 
difference in biofilm formation, efflux activity or competitive fitness (data not shown). 919 
The integration vector (pDOC-K/ glms) was generated by cloning of the first 920 
homologous region in MCS1 of pDOC-K, using EcoRI/ KpnI and the second 921 
homologous region in MCS2 using XhoI/ NheI. The primer used for the amplification 922 
of the second homologous region was designed to introduce a novel MCS (XhoI, 923 
NdeI, SmaI, NotI, HindIII), upstream of the second homologous region which was 924 
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then used for the gene complementation constructs. Wild-type ramR and ‘ramR-925 
T18P’ alleles were cloned XhoI/ HindIII in pDOC-K/ glms under the control of the 926 
gene’s native promoter. Wild-type envZ and ‘envZ-SNP’ alleles were cloned XhoI/ 927 
HindIII in pDOC-K/ glms under the control of a constitutive plac promoter. For acrB 928 
complementation, we used the pWKS30/ AcrB plasmid previously described in (61), 929 
expression of the gene is under the control of the pBAD system and induction was 930 
achieved with the use of 0.5% arabinose.  931 
For induction of chromosomal integrations either for deletion or complementation of 932 
a gene, the strain to be modified was transformed with the pDOC-K vector variant 933 
and the pACBSCE helper plasmid carrying the λ-red genes. A single colony carrying 934 
both plasmids was grown in 500 μL of LB, at 37 oC for 4 hours. The cells were 935 
pelleted and washed three times in filter sterilized LB. They were then resuspended 936 
in 500 μL of 0.1x LB supplemented with 0.3% arabinose and incubated at 37 oC for 937 
2-3 hours for induction. 100 μL were plated on LB plates supplemented with 25 μg/ 938 
mL kanamycin and 5% sucrose. The plates were incubated overnight at 37 oC. 939 
Single colonies were checked for chromosomal alterations using colony PCR with 940 
primers annealing outside of the region to be modified. The plasmids were removed 941 
by sub culturing the positive clones on kanamycin-supplemented plates and testing 942 
them for chloramphenicol and ampicillin sensitivity until the plasmids were 943 
completely removed.  944 
For ‘double deletions’ and/or complementations, the kanamycin cassette, introduced 945 
by the first chromosomal modification, was removed using the FLP sites flanking the 946 
cassette. The strains were transformed by electroporation with the pCP20 vector, 947 
carrying the genes for flippase activity, and recovered on LB agar plates 948 
supplemented with 50 μg/mL ampicillin at 30 oC. The kanamycin cassette removal 949 
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was confirmed by colony PCR and the positive clones were sub-cultured on LB agar 950 
at 37-42 oC. Removal of the plasmid was confirmed by testing the colonies’ 951 
sensitivity to ampicillin.  952 
  953 
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Figures 1154 
 1155 
Figure 1: Salmonella biofilm adaptation model. a, Sterile glass beads were used 1156 
for the establishment of Salmonella biofilms. Three antibiotics were selected and used 1157 
as stressors; azithromycin, cefotaxime and ciprofloxacin. b, For each experiment, 1158 
eight independent lineages were ran in parallel; two planktonic controls, exposed to 1159 
the drug, with no beads present; two bead controls, not exposed to the drug, and four 1160 
independent lineages, exposed to the drug on beads. c, Passages and sampling were 1161 
carried out every 72 hours at 30 oC and the cells isolated were stored and phenotyped 1162 
for biofilm formation, fitness, susceptibility etc. d, Over 100 strains (populations and 1163 
single-cell isolates) were selected and sequenced based on their phenotypic 1164 
characteristics. e, To determine the right experimental conditions for the evolution 1165 
experiment, cells were recovered and counted from biofilms grown for different periods 1166 
of time, at different temperatures. This showed that the maximum cell carriage is 1167 
achieved by 72 h at either 25 oC or 30 oC. Dots indicate average from 4 replicates and 1168 
error bars show standard error f. To determine whether bacteria adapt to the bead 1169 
model, biofilm formation was monitored over time by visualisation on Congo red-1170 
supplemented plates and by the Crystal Violet assay (OD:590nm), using the 1171 
unexposed bead control lineages. The strains quickly adapted and produced 1172 
significantly more biomass compared to the WT by the end of the experiment. Each 1173 
dot represents single cell strains isolated from different timepoints. Error bars reflect 1174 
estimated +/- one standard error. 1175 
 1176 
 1177 
 1178 
 1179 
 1180 
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 1181 
 Figure 2: Biofilms adapt to antibiotic stress, with diverse effects on biofilm 1182 
formation. Planktonic and biofilm populations, exposed to azithromycin (a-b), 1183 
cefotaxime (c-d) and ciprofloxacin (e-f) were isolated at different timepoints during the 1184 
evolution experiment (early, mid, late). Panels on the left show data from planktonic 1185 
lineages, panels on the right from biofilm lineages. Three single isolates per timepoint 1186 
were tested for their biofilm ability and susceptibility. Biofilm formation was measured 1187 
by the Crystal Violet assay and on Congo Red plates. Unexposed biofilm lineages 1188 
were used as a reference to biofilm adaptation (results shown in grey on CV graphs). 1189 
Antibiotic susceptibility was determined by measuring the MIC values for a panel of 1190 
different antimicrobials (azithromycin, cefotaxime, chloramphenicol, ciprofloxacin, 1191 
kanamycin, nalidixic acid, tetracycline and triclosan). Stacked bars were generated by 1192 
stacking the average MICs for each antibiotic (colour-coded), from three single cell 1193 
isolates a-b, Both planktonic and biofilm isolates, exposed to azithromycin, developed 1194 
resistance to azithromycin as well as decreased susceptibility to cefotaxime, 1195 
chloramphenicol, ciprofloxacin, nalidixic acid, tetracycline and triclosan. Biofilm 1196 
adaptation was inhibited in the biofilm lineages. c-d, Planktonic lineages, exposed to 1197 
cefotaxime, rapidly developed resistance to cefotaxime. Biofilms under the same 1198 
exposure exhibited an MDR response. Biofilm adaptation of both planktonic and 1199 
biofilm lineages was completely compromised leading to pale colonies on CR plates. 1200 
e-f, Planktonic and biofilm lineages exposed to ciprofloxacin adapted to the stress by 1201 
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developing resistance to the stressor. Biofilm adaptation was delayed compared to the 1202 
unexposed control lineages but significantly increased by the end of the experiment. 1203 
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Figure 3: Correlations between resistance and biofilm formation selected by 1205 
different antibiotics. a-h, Fold change in MIC for each antibiotic was compared 1206 
against the fold change in biofilm formation. Single isolates were characterised; with 1207 
each dot on the graphs representing an individual isolate from each evolution 1208 
experiment (blue: azithromycin, white: cefotaxime, red: ciprofloxacin, black: drug-free 1209 
controls). The parent strain average, used as a reference, is represented as point ‘0,0’ 1210 
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on the graphs. Azithromycin and cefotaxime exposed isolates became less 1211 
susceptible not only to the stressor but also to other antimicrobials. Ciprofloxacin-1212 
exposed isolates only became resistant to fluoroquinolones. Biofilm formation was 1213 
heavily compromised in cefotaxime-exposed strains. Azithromycin inhibited biofilm 1214 
formation with some strains exhibiting slightly reduced levels of biofilm formation, 1215 
whereas ciprofloxacin did not have a significant effect on biofilm adaptation. 1216 
 1217 
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Figure 4. Phylogenetic analysis and AcrB modelling. a, Universal phylogenetic 1220 
tree based on full genome alignment, showing diversity of strains exposed to 1221 
azithromycin, cefotaxime and ciprofloxacin. Azithromycin and cefotaxime selected for 1222 
mutants that followed a distinct evolution pattern, whereas ciprofloxacin-exposed 1223 
strains evolved and responded to the stress in various ways. S. Typhimurium 1224 
14028S (CP001363) was used as the reference strain and the tree was arbitrarily 1225 
rooted at the cultivated parental sequence 14028S. b-d, Individual trees were 1226 
generated for cefotaxime, azithromycin and ciprofloxacin-exposed strains. Dark dots 1227 
indicate biofilm lineages, light dots planktonic lineages. Phylogenetic variations 1228 
between biofilms and planktonic cultures were observed, indicating unique 1229 
mechanisms of resistance between the two states. e, Cefotaxime binding to the 1230 
distal binding pocket of AcrB (4DX5, chain B). Q176 is involved in the coordination of 1231 
cephalosporin molecules in the binding pocket. f, Upon substitution with lysine 1232 
(Q176K), the free energy of binding changed significantly, potentially resulting in 1233 
reduced residence time of the drug in the pocket and hence, increased efflux g, 1234 
Azithromycin docking to macrolide site A of the proximal binding pocket of AcrB 1235 
(3AOB, chain C). R717 exhibits a direct involvement in macrolide coordination in the 1236 
pocket. h, Substitution with leucine (R717L) led to radically altered coordination of 1237 
azithromycin in the pocket. 1238 
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      1240 
Figure 5: Proposed novel mechanism of resistance to cefotaxime and 1241 
azithromycin. a-i, Cefotaxime and azithromycin exposed isolates exhibiting decreased 1242 
susceptibility, were whole-genome-sequenced and genetic variations were identified. a, 1243 
Cefotaxime exposed isolates from the middle timepoint carried the R397H substitution in 1244 
EnvZ leading to reduced susceptibility to cefotaxime and chloramphenicol. Isolates from the 1245 
late timepoint carried an additional Q176H substitution in AcrB (efflux pump). This resulted in 1246 
an increase in MIC for both cefotaxime and chloramphenicol as well as tetracycline. Deletion 1247 
and complementation of WT envZ had no effect on resistance while complementation with 1248 
the R397H variant, reproduced the resistance results from the isolated strain. Deletion of 1249 
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acrB led to increased susceptibility against all efflux substrate antibiotics. Complementation 1250 
with AcrB Q176K variant, in the ΔAcrB/ ΔRamR background, resulted in complete recovery 1251 
of the resistant phenotype. b, q RT-PCR from 48-hour biofilms, using gyrB as a reference, 1252 
resulted in significantly reduced ompF (large porin) expression, whereas ompC (narrow 1253 
porin) expression significantly increased. c, Expression of csgA/B (main curli subunits) was 1254 
abolished, explaining the pale morphotype cefotaxime-resistant-mutants exhibited. d, To test 1255 
whether the changes on porin composition affect membrane permeability, drug accumulation 1256 
was measured using the resazurin assay. A tolC::cat, pump-defective mutant, was used as a 1257 
control. Both resistant mutants exhibited decreased drug accumulation, reflective of the 1258 
altered membrane composition. e, Resistance against cefotaxime is a synergistic result of 1259 
reduced membrane permeability due to porin alterations and increased efflux through the 1260 
AcrA/B-TolC pump. f, Azithromycin exposed strains, from an early time point, obtained an 1261 
AcrB R717L substitution which led to an 8-fold increase in azithromycin MIC. At a later 1262 
stage, an additional substitution in RamR (T18P) emerged. This resulted in an MDR 1263 
phenotype with increased MICs of azithromycin, chloramphenicol, nalidixic acid and 1264 
tetracycline. Complementation of AcrB R717L in the ΔAcrB and of the RamR T18P in the 1265 
ΔRamR background reproduced the resistance profiles of the strains isolated from the 1266 
evolution experiments, confirming that these substitutions are responsible for the resistant 1267 
phenotypes observed. g, Expression of acrB and ramA were monitored by q RT-PCR in 48-1268 
hour biofilms and showed increased expression of both acrB and ramA in the isolate 1269 
carrying the RamR T18P substitution. h, Membrane permeability was monitored by the 1270 
resazurin assay and reduced accumulation was observed because of the RamR T18P 1271 
substitution, which potentially leads to overexpression of the RND pump. i, Resistance 1272 
against azithromycin is a result of the modification of the AcrA/B-TolC pump, leading to 1273 
increased efflux and overexpression of it due to the absence of negative regulation in the 1274 
RamR T18P substitution strain.   1275 
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 1277 
 1278 
Figure 6: Consequences of resistance. a, Unexposed biofilm-adapted lineages were 1279 
tested for resistance over time with no changes observed in their resistance score (additive value of 1280 
All rights reserved. No reuse allowed without permission. 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/605212doi: bioRxiv preprint first posted online Apr. 10, 2019; 
 59 
 
all MICs determined for a strain). b, Although the strains adapted to forming better biofilms over 1281 
time, their resistance score did not change. c, Biofilm viability was tested on 72-hour-biofilms grown 1282 
on coverslips after treatment with increasing amounts of ciprofloxacin (0, 0.03, 0.3, 3 μg/mL). The 1283 
strains tested were: cip-plank-L-S1 (resistant but low-biofilm former), control-L-S1 (not resistant but 1284 
good biofilm former) and cip-biofilm-L-B-S3 (resistant and good biofilm former). Only biofilms 1285 
produced by cip-biofilm-L-B-S3 were significantly harder to kill with ciprofloxacin. d, 72-hour-biofilms 1286 
grown on coverslips were pre-treated with 3 μg/mL ciprofloxacin for 90 minutes, they were stained 1287 
with live/dead stain and fluorescence microscopy was performed in a Zeiss Axio Imager M2. Different 1288 
strains formed biofilms of variable density. An increased number of live cells was only observed in 1289 
biofilms produced by the cip-biofilm-L-B-S3 strain, with surviving cells forming dense clusters on the 1290 
coverslip. e, Pathogenicity (bars) was tested in the Galleria mellonella infection model. Each point 1291 
indicates the average number of survivors from independent experiments and the bars show the 1292 
average of these. The strains tested exhibited resistant phenotypes, with diverse biofilm abilities. WT 1293 
and the unexposed control-L-S1 strain were used as a reference to the assay. Biofilm formation (lines) 1294 
was measured by the CV assay and on CR plates. Survival was directly correlated with biofilm 1295 
formation, with the weak biofilm formers causing more deaths in this model. f, Stability of resistance 1296 
was measured by calculating the average of fold change in MIC per antibiotic, after ten 24-hour 1297 
passages without any stressor present. For most antibiotics, resistance was stable throughout the 1298 
accelerated evolution experiment except for cefotaxime. g, Biofilm formation increased significantly 1299 
for the majority of the tested strains, by the end of the experiment. h, Individual example of an 1300 
azithromycin resistant strain, which adapted and formed better biofilm over time without losing 1301 
resistance to azithromycin. Pink line shows the changes in azithromycin MIC over time (line graph, 1302 
left axis). Bars (bar chart, right axis) show the average biofilm formation from three replicates. Error 1303 
bars indicate standard deviation   i, Individual example of a cefotaxime resistant strain, which 1304 
adapted to forming better biofilm but lost the resistance to cefotaxime. Purple line shows the 1305 
changes in cefotaxime MIC over time (line graph, left axis). Bars and error bars are as above.   1306 
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Tables 1307 
Table 1. Bacterial strains and vectors 1308 
 1309 
Constructs/ Vectors  Source/ 
Reference 
Description 
pDOC-K (60) Gene doctoring deletion backbone 
pACBSCE (60) Gene doctoring helper plasmid 
pDOC-K/ acrB Webber group acrB deletion construct 
pDOC-K/ ramR Webber group ramR deletion construct 
pDOC-K/ yjcC Webber group  yjcC deletion construct 
pDOC-K/ envZ Webber group envZ deletion construct 
pDOC-K/ glms  Webber group Gene doctoring complementation backbone 
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pDOC-K/ glms/ ramR Webber group ramR complementation construct, under native promoter 
pDOC-K/ glms/ ramR T18P Webber group ramR T18P complementation construct, under native promoter 
pDOC-K/ glms/ envZ Webber group envZ complementation construct, under constitutive plac promoter 
pDOC-K/ glms/ envZ R397H Webber group envZ R397H complementation construct, under constitutive plac 
promoter 
pWKS30/ acrB (61) acrB complementation construct, under arabinose-inducible pbad 
promoter 
pWKS30/ acrB Q176K Webber group acrB-Q176K complementation construct, under arabinose-
inducible pbad promoter 
pWKS30/ acrB R717L Webber group acrB-R717L complementation construct, under arabinose-
inducible pbad promoter 
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Strains  Source/ 
Reference 
Description 
Salmonella enterica serovar Typhimurium  
(14028S) 
(62) Wild type strain  
14028S/ ΔacrB Webber group acrB deletion strain 
14028S/ ΔramR Webber group ramR deletion strain  
14028S/ ΔenvZ Webber group envZ deletion strain  
14028S/ ΔacrB/ pacrB Webber group acrB complementation strain 
14028S/ ΔacrB/ pacrB R717L Webber group acrB R717L complementation strain 
14028S/ ΔramR/ pramR Webber group ramR complementation strain  
14028S/ ΔramR/ pramR T18P Webber group ramR T18P complementation strain 
14028S/ ΔenvZ/ penvZ Webber group envZ complementation strain 
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14028S/ ΔenvZ/ penvZ R397H Webber group envZ R397H complementation strain 
14028S/ ΔacrB/ ΔramR Webber group Double deletion strain  
14028S/ ΔacrB/ ΔramR/ pacrB Webber group Double deletion strain/ acrB complementation 
14028S/ ΔacrB/ ΔramR/ pacrB (R717L) Webber group Double deletion strain/ acrB complementation-SNP variation 
 1310 
Table 2. Primers used in this study 1311 
Name Sequence Use 
AcrB-part1 for 
(EcoRI) 
TACGTGAATTCCACGCGGCGATGCCACGGTG acrB deletion 
AcrB-part1 Rev 
(BamHI) 
GCATAGGATCCAAATATAGGGCGATCGATAA acrB deletion 
AcrB-part2 for 
(XhoI) 
TACGTCTCGAGATTGAGCATAGTCATTCGAC acrB deletion 
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AcrB-part2 Rev 
(NheI) 
GCATAGCTAGCGTTTGTGTAATCATTGGGTT acrB deletion 
RamR part1-For 
(EcoRI) 
TACGTGAATTCAAACTCGTCAGCGGCTCCCG ramR deletion 
RamR-part1 Rev 
(BamHI) 
GCATAGGATCCTTTTTTGTCTTCACTCTTCG ramR deletion 
RamR-part2 for 
(XhoI) 
TACGTCTCGAGTGGCGCGCGCTGACTCGCGA ramR deletion 
RamR-part2 Rev 
(NheI) 
GCATAGCTAGCTATCCTCGCCCGCATAGACT ramR deletion 
EnvZ_part1_For 
(EcoRI)  
TACGTGAATTCCGCGAGATGTTC envZ deletion 
EnvZ_part1_Rev 
(BamHI) 
GGATCCGGATCCAACTTCGC envZ deletion 
EnvZ_part2_For 
(XhoI) 
TACGTCTCGAGCGCGTCCAG envZ deletion 
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EnvZ_part2_Rev 
(SpeI) 
AGTACTAGTGCTGTTCGATCTGGCGATCCCGAC envZ deletion 
Glms_part1_For 
(EcoRI) 
TACGTGAATTCGCTCGAAGGCGCGCTGAAG pDOC-K/glms 
generation 
Glms_part1_Rev 
(KpnI) 
ACGTAGGTACCCGGCCTTCTGCCTGGTACTACATTTG pDOC-K/glms 
generation 
Glms_part2_for 
(XhoI)-MCS 
TACGTCTCGAGCATATGCCCGGGGCGGCCGCAAGCTTTCGACAGACGGCCTTTTT
TTG 
pDOC-K/glms 
generation 
Glms_part2_Rev 
(NheI) 
GCATAGCTAGCCGGTCAATTTCCCCATTCCC pDOC-K/glms 
generation 
RamR-compl-For 
(XhoI) 
 
GCATACTCGAGTTCATGCGGCAGCCCTTG 
 
ramR 
complementation 
RamR-compl-Rev 
(HindIII) 
 
ACGTAAAGCTTTTATTGCTCCTCGCGAGTCAGC 
 
ramR 
complementation 
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EnvZ-compl-For 
(XhoI) 
ATCACTCTCGAGTTTACACTTTATGCTTCCGGCTCGTATGTTGCAGACCGTCTGGG
GCCTGG 
 
envZ 
complementation 
EnvZ-compl-Rev 
(HindIII) 
GGACGTAAGCTTTTATGCCTCTTTTGTCGTCCCCTGGAC 
 
envZ 
complementation 
GyrB-RT-For GGAAGGGGACTCCGCGGGCG q-RT PCR 
GyrB-RT-Rev CAGCGGCGGCTGCGCAATGT q-RT PCR 
RamA-RT-For CGCTCAGGTTATCGACACGA q-RT PCR 
RamA-RT-Rev CCACTTGGAATACCCCGCAT q-RT PCR 
OmpF-RT-For GGCGGCGCCTATACTGATAA q-RT PCR 
OmpF-RT-Rev CGAAAGAGAGACCGTCCACC q-RT PCR 
OmpC-RT-For TTATGCAATCGGCGAAGGCT q-RT PCR 
OmpC-RT-Rev GTTACCATACAGGCGAGCGT q-RT PCR 
CsgA-RT-For CATCGACCAGTGGAACGCTA q-RT PCR 
CsgA-RT-Rev TACGCTGGAATCAGATGCGG q-RT PCR 
CsgB-RT-For TGCAACCGCGACAAATTATGA q-RT PCR 
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CsgB-RT-Rev TTGACCAATAATGGCCGCCT q-RT PCR 
 1312 
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